Edgewise Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
EWTX$46.53-4.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(In thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Nine months ended September 30, | ||||||
| · · 2026 · · 2025 | ||||||
| Cash flows from operating activities · · · · · | ||||||
| Net income (loss) | | $1,059,811 | | $(117,579) | ||
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | | | | | ||
| Depreciation | | | 1,608 | | 1,559 | |
| Stock-based compensation | | 26,641 | | 24,877 | ||
| Gain on the Sevasemten Sale | | | (1,348,066) | | — | |
| Accretion of discount on marketable securities, net | | | (4,547) | | | (6,182) |
| Amortization of right-of-use asset | | | 169 | | | 132 |
| Changes in assets and liabilities: | | | | | ||
| Prepaid expenses and other assets | | (16,849) | | (5,248) | ||
| Accounts payable | | 8,830 | | 575 | ||
| Accrued compensation | | (3,625) | | (2,058) | ||
| Accrued other expenses and other liabilities | | 4,429 | | (745) | ||
| Accrued taxes | | | 108,901 | | | — |
| Lease liability | | (605) | | | (555) | |
| Net cash used in operating activities | | (163,303) | | | (105,224) | |
| | | | | | | |
| Cash flows from investing activities | | | | | | |
| Purchases of marketable securities | | (1,567,519) | | (452,941) | ||
| Sales of marketable securities | | | 45,253 | | | 51,452 |
| Maturities of marketable securities | | | 314,282 | | | 319,120 |
| Proceeds from the Sevasemten Sale, net of transaction costs | | | 1,348,891 | | | — |
| Purchases of property and equipment | | (309) | | (183) | ||
| Net cash provided by (used in) investing activities | | 140,598 | | (82,552) | ||
| | | | | | | |
| Cash flows from financing activities | | | | | ||
| Proceeds from issuance of common stock, net of offering costs | | | — | | | 187,362 |
| Exercise of stock options | | 29,444 | | 4,153 | ||
| Payment of deferred offering costs | | | — | | | — |
| Proceeds from Employee Stock Purchase Plan | | | 793 | | | 598 |
| Net cash provided by financing activities | | 30,237 | | 192,113 | ||
| | | | | | | |
| Net change in cash and cash equivalents | | 7,532 | | 4,337 | ||
| Cash and cash equivalents at beginning of period | | 61,148 | | 41,666 | ||
| Cash and cash equivalents at end of period | | $68,680 | | $46,003 | ||
| Supplemental disclosures of non-cash investing activities: | | | | | ||
| Property and equipment purchases included in accounts payable | | $— | | $47 | ||
| Supplemental disclosures of cash flow information: | | | | | | |
| Cash paid for income taxes, net(1) | | $46,432 | | $— | ||
| (1) | For the nine months ended September 30, 2026, the amount includes $23.2 million paid to purchase transferable federal income tax credits that were utilized during the period. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.